Addex Therapeutics Ltd (ADXN.SW)
CHF 0.05
(0.0%)
CHF 0.05
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.64 Million CHF | -43.96% |
| 2022 | 8.28 Million CHF | -63.26% |
| 2021 | 22.54 Million CHF | 11.69% |
| 2020 | 20.18 Million CHF | -38.9% |
| 2019 | 33.02 Million CHF | -21.76% |
| 2018 | 42.21 Million CHF | 1278.1% |
| 2017 | 3.06 Million CHF | 82.02% |
| 2016 | 1.68 Million CHF | -41.76% |
| 2015 | 2.88 Million CHF | -27.74% |
| 2014 | 3.99 Million CHF | -31.98% |
| 2013 | 5.87 Million CHF | -72.95% |
| 2012 | 21.73 Million CHF | -50.17% |
| 2011 | 43.61 Million CHF | -41.28% |
| 2010 | 74.28 Million CHF | -16.11% |
| 2009 | 88.55 Million CHF | -33.08% |
| 2008 | 132.32 Million CHF | -11.41% |
| 2007 | 149.37 Million CHF | 222.26% |
| 2006 | 46.35 Million CHF | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 13.69 Million CHF | 310.87% |
| 2024 Q1 | 3.33 Million CHF | -28.17% |
| 2023 Q3 | 6.13 Million CHF | -31.79% |
| 2023 Q4 | 4.64 Million CHF | -24.39% |
| 2023 FY | 4.64 Million CHF | -43.96% |
| 2023 Q2 | 8.99 Million CHF | 23.36% |
| 2023 Q1 | 7.29 Million CHF | -11.92% |
| 2022 FY | 8.28 Million CHF | -63.26% |
| 2022 Q4 | 8.28 Million CHF | -32.34% |
| 2022 Q3 | 12.24 Million CHF | 7.55% |
| 2022 Q1 | 17.68 Million CHF | -21.56% |
| 2022 Q2 | 11.38 Million CHF | -35.63% |
| 2021 Q2 | 21.53 Million CHF | -19.88% |
| 2021 FY | 22.54 Million CHF | 11.69% |
| 2021 Q1 | 26.87 Million CHF | 33.16% |
| 2021 Q4 | 22.54 Million CHF | 24.82% |
| 2021 Q3 | 18.06 Million CHF | -16.12% |
| 2020 FY | 20.18 Million CHF | -38.9% |
| 2020 Q1 | 28.87 Million CHF | -12.58% |
| 2020 Q3 | 19.64 Million CHF | -15.12% |
| 2020 Q4 | 20.18 Million CHF | 2.73% |
| 2020 Q2 | 23.14 Million CHF | -19.84% |
| 2019 Q1 | - CHF | -100.0% |
| 2019 Q2 | 37.96 Million CHF | 0.0% |
| 2019 Q4 | 33.02 Million CHF | 0.0% |
| 2019 FY | 33.02 Million CHF | -21.76% |
| 2018 Q2 | 44.87 Million CHF | 0.0% |
| 2018 Q1 | 44.87 Million CHF | 1364.83% |
| 2018 Q3 | 42.21 Million CHF | -5.92% |
| 2018 FY | 42.21 Million CHF | 1278.1% |
| 2018 Q4 | 42.21 Million CHF | 0.0% |
| 2017 FY | 3.06 Million CHF | 82.02% |
| 2017 Q4 | 3.06 Million CHF | 0.0% |
| 2017 Q3 | 3.06 Million CHF | -20.38% |
| 2017 Q2 | 3.84 Million CHF | 0.0% |
| 2017 Q1 | 3.84 Million CHF | 128.61% |
| 2016 Q2 | 2.6 Million CHF | 0.0% |
| 2016 Q4 | 1.68 Million CHF | 0.0% |
| 2016 Q3 | 1.68 Million CHF | -35.3% |
| 2016 Q1 | 2.6 Million CHF | -9.98% |
| 2016 FY | 1.68 Million CHF | -41.76% |
| 2015 Q4 | 2.88 Million CHF | 0.0% |
| 2015 FY | 2.88 Million CHF | -27.74% |
| 2015 Q2 | 3.89 Million CHF | 0.0% |
| 2015 Q1 | 3.89 Million CHF | -2.48% |
| 2015 Q3 | 2.88 Million CHF | -25.9% |
| 2014 Q2 | 4.41 Million CHF | 0.0% |
| 2014 Q4 | 3.99 Million CHF | 0.0% |
| 2014 Q3 | 3.99 Million CHF | -9.34% |
| 2014 FY | 3.99 Million CHF | -31.98% |
| 2014 Q1 | 4.41 Million CHF | -24.97% |
| 2013 Q2 | 9.44 Million CHF | 0.0% |
| 2013 Q1 | 9.44 Million CHF | -56.53% |
| 2013 FY | 5.87 Million CHF | -72.95% |
| 2013 Q4 | 5.87 Million CHF | 0.0% |
| 2013 Q3 | 5.87 Million CHF | -37.78% |
| 2012 Q4 | 21.73 Million CHF | 0.0% |
| 2012 Q3 | 21.73 Million CHF | -22.76% |
| 2012 FY | 21.73 Million CHF | -50.17% |
| 2012 Q2 | 28.14 Million CHF | 0.0% |
| 2011 Q4 | 43.61 Million CHF | 0.0% |
| 2011 FY | 43.61 Million CHF | -41.28% |
| 2011 Q2 | 59.54 Million CHF | 0.0% |
| 2010 Q2 | 68.15 Million CHF | 0.0% |
| 2010 Q4 | 74.28 Million CHF | 0.0% |
| 2010 FY | 74.28 Million CHF | -16.11% |
| 2009 FY | 88.55 Million CHF | -33.08% |
| 2009 Q4 | 88.55 Million CHF | 0.0% |
| 2008 FY | 132.32 Million CHF | -11.41% |
| 2007 FY | 149.37 Million CHF | 222.26% |
| 2006 FY | 46.35 Million CHF | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| BB Biotech AG | 2.63 Billion CHF | 99.824% |
| Basilea Pharmaceutica AG | 173.28 Million CHF | 97.322% |
| Evolva Holding SA | 9.82 Million CHF | 52.778% |
| Idorsia Ltd | 499.99 Million CHF | 99.072% |
| Kuros Biosciences AG | 75.9 Million CHF | 93.886% |
| Molecular Partners AG | 198.35 Million CHF | 97.66% |
| Relief Therapeutics Holding AG | 76.39 Million CHF | 93.925% |
| Santhera Pharmaceuticals Holding AG | 109.62 Million CHF | 95.767% |